NUVECTIS PHARMA INC. - COMMON STOCK

Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC

04 мар 2025 07:00:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights

25 фев 2025 07:00:01 Источник Nasdaq GlobeNewswire

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option

07 фев 2025 07:30:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

05 фев 2025 08:01:33 Источник Nasdaq GlobeNewswire

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

04 фев 2025 15:05:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium

10 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer

14 ноя 2024 06:00:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

05 ноя 2024 06:00:21 Источник Nasdaq GlobeNewswire

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics

23 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

07 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference

05 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

29 авг 2024 07:00:42 Источник Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

06 авг 2024 07:28:42 Источник Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

16 май 2024 07:30:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

07 май 2024 07:00:16 Источник Nasdaq GlobeNewswire

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

08 апр 2024 07:30:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting

19 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma to Present at the 36th Annual Roth Conference

15 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

14 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights

05 мар 2024 07:00:20 Источник Nasdaq GlobeNewswire